Stock Analysis on Net

Medtronic PLC (NYSE:MDT)

$24.99

Analysis of Long-term (Investment) Activity Ratios
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Long-term Activity Ratios (Summary)

Medtronic PLC, long-term (investment) activity ratios (quarterly data)

Microsoft Excel
Jan 23, 2026 Oct 24, 2025 Jul 25, 2025 Apr 25, 2025 Jan 24, 2025 Oct 25, 2024 Jul 26, 2024 Apr 26, 2024 Jan 26, 2024 Oct 27, 2023 Jul 28, 2023 Apr 28, 2023 Jan 27, 2023 Oct 28, 2022 Jul 29, 2022 Apr 29, 2022 Jan 28, 2022 Oct 29, 2021 Jul 30, 2021 Apr 30, 2021 Jan 29, 2021 Oct 30, 2020 Jul 31, 2020
Net fixed asset turnover
Total asset turnover
Equity turnover

Based on: 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).


The long-term investment activity ratios demonstrate varied trends over the observed period. Generally, the ratios indicate a moderate level of asset utilization, with some evidence of evolving efficiency. A consistent downward trend emerges in the latter portion of the period, particularly for the net fixed asset turnover ratio, while the total and equity turnover ratios exhibit more stability, and even some improvement in later quarters.

Net Fixed Asset Turnover
The net fixed asset turnover ratio began at 5.72 and generally fluctuated between 5.56 and 6.13 for the first several quarters. However, a clear downward trend is observed from the period ending July 2022 (5.88) through January 2026 (4.94). This suggests a decreasing efficiency in generating revenue from fixed assets. The decline is gradual but consistent, falling from approximately 5.88 to 4.94 over the course of ten quarters. This could indicate overinvestment in fixed assets, underutilization of existing assets, or a decline in sales relative to fixed asset investment.
Total Asset Turnover
The total asset turnover ratio shows a more stable pattern. It started at 0.30 and increased to a peak of 0.35 between October 2021 and April 2022, remaining relatively consistent at that level for several quarters. A slight decline is noted from October 2022 (0.33) through January 2025 (0.37), followed by a modest increase to 0.39 by January 2026. Overall, the ratio demonstrates a relatively healthy level of asset utilization, with minor fluctuations. The ratio suggests that for every dollar of assets, approximately $0.35 to $0.39 of revenue is generated.
Equity Turnover
The equity turnover ratio exhibits an upward trend throughout the observed period. Starting at 0.56, it gradually increased to 0.72 by January 2026. This indicates an increasing efficiency in generating revenue from shareholder equity. The increase is consistent, suggesting that the company is becoming more effective at utilizing equity financing to generate sales. The ratio suggests that for every dollar of equity, approximately $0.56 to $0.72 of revenue is generated.

In summary, while the total asset turnover ratio remains relatively stable, the declining net fixed asset turnover ratio warrants further investigation. The increasing equity turnover ratio is a positive sign, indicating improved efficiency in utilizing equity financing. The interplay between these ratios suggests a potential shift in the company’s asset base and financing strategies.


Net Fixed Asset Turnover

Medtronic PLC, net fixed asset turnover calculation (quarterly data)

Microsoft Excel
Jan 23, 2026 Oct 24, 2025 Jul 25, 2025 Apr 25, 2025 Jan 24, 2025 Oct 25, 2024 Jul 26, 2024 Apr 26, 2024 Jan 26, 2024 Oct 27, 2023 Jul 28, 2023 Apr 28, 2023 Jan 27, 2023 Oct 28, 2022 Jul 29, 2022 Apr 29, 2022 Jan 28, 2022 Oct 29, 2021 Jul 30, 2021 Apr 30, 2021 Jan 29, 2021 Oct 30, 2020 Jul 31, 2020
Selected Financial Data (US$ in millions)
Net sales
Property, plant, and equipment, net
Long-term Activity Ratio
Net fixed asset turnover1
Benchmarks
Net Fixed Asset Turnover, Competitors2
Abbott Laboratories
Elevance Health Inc.
Intuitive Surgical Inc.
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).

1 Q3 2026 Calculation
Net fixed asset turnover = (Net salesQ3 2026 + Net salesQ2 2026 + Net salesQ1 2026 + Net salesQ4 2025) ÷ Property, plant, and equipment, net
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The net fixed asset turnover ratio for the observed period demonstrates a generally declining trend, although with some fluctuations. Initially, the ratio exhibited relative stability before a noticeable decrease in later periods. This suggests a changing relationship between net sales and the company’s investment in fixed assets.

Initial Period (Jul 31, 2020 – Oct 29, 2021)
The ratio began at 5.72 and fluctuated within a narrow range, peaking at 6.13. This indicates a consistent level of sales generation relative to the fixed asset base during this timeframe. The slight variations likely reflect seasonal sales patterns or short-term operational changes.
Transitional Phase (Jan 28, 2022 – Oct 28, 2022)
A gradual downward trend commenced, with the ratio declining from 6.05 to 5.82. While the decrease is moderate, it signals a potential shift in the efficiency of fixed asset utilization. Net sales experienced some volatility during this period, which contributed to the ratio’s decline.
Accelerated Decline (Jan 27, 2023 – Oct 24, 2025)
The ratio experienced a more pronounced decline, falling from 5.66 to 4.94. This suggests that the company is generating less revenue for each dollar invested in fixed assets. The continued investment in property, plant, and equipment, net, coupled with relatively stable or slightly declining net sales, likely contributed to this trend. The lowest point was reached in April 2025 at 4.91.
Overall Trend
Over the entire period, the net fixed asset turnover ratio decreased from 5.72 to 4.94. This represents a roughly 14% decrease, indicating a reduced efficiency in utilizing fixed assets to generate sales. Further investigation would be needed to determine the underlying causes, such as increased asset intensity, slower sales growth, or changes in production processes.

The observed trend warrants further scrutiny to understand the drivers behind the decreasing efficiency. Potential areas of investigation include capital expenditure decisions, asset utilization strategies, and sales performance relative to industry peers.


Total Asset Turnover

Medtronic PLC, total asset turnover calculation (quarterly data)

Microsoft Excel
Jan 23, 2026 Oct 24, 2025 Jul 25, 2025 Apr 25, 2025 Jan 24, 2025 Oct 25, 2024 Jul 26, 2024 Apr 26, 2024 Jan 26, 2024 Oct 27, 2023 Jul 28, 2023 Apr 28, 2023 Jan 27, 2023 Oct 28, 2022 Jul 29, 2022 Apr 29, 2022 Jan 28, 2022 Oct 29, 2021 Jul 30, 2021 Apr 30, 2021 Jan 29, 2021 Oct 30, 2020 Jul 31, 2020
Selected Financial Data (US$ in millions)
Net sales
Total assets
Long-term Activity Ratio
Total asset turnover1
Benchmarks
Total Asset Turnover, Competitors2
Abbott Laboratories
Elevance Health Inc.
Intuitive Surgical Inc.
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).

1 Q3 2026 Calculation
Total asset turnover = (Net salesQ3 2026 + Net salesQ2 2026 + Net salesQ1 2026 + Net salesQ4 2025) ÷ Total assets
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The total asset turnover ratio for the analyzed period demonstrates a generally increasing trend, albeit with some fluctuations. Initially, the ratio stood at 0.30 in July 2020, and exhibited relative stability through January 2022, hovering around 0.35. A consistent upward trajectory is then observed from October 2022, culminating in a ratio of 0.39 in January 2026. This suggests a growing efficiency in utilizing assets to generate sales over the observed timeframe.

Initial Period (July 2020 – January 2022)
The ratio remained relatively stable, fluctuating between 0.29 and 0.35. This indicates a consistent, but not significantly improving, level of asset utilization during this period. Minor variations likely reflect seasonal sales patterns or short-term operational adjustments.
Ascending Trend (October 2022 – January 2026)
A clear upward trend emerges, with the ratio increasing from 0.33 to 0.39. This signifies that the company is becoming more effective at generating sales revenue from its asset base. The consistent increase suggests a sustained improvement in operational efficiency or a strategic shift towards more asset-lean revenue generation.
Quarterly Fluctuations
While the overall trend is upward, quarterly variations are present. For example, a slight decrease is observed between July 2022 (0.35) and October 2022 (0.33). These fluctuations are normal and can be attributed to various factors, including changes in inventory levels, accounts receivable collection periods, and overall economic conditions. However, these fluctuations do not disrupt the overarching positive trend.
Peak Performance
The highest ratio recorded is 0.39, appearing in both January 2026 and October 2025. This represents the most efficient period for asset utilization within the analyzed timeframe, indicating optimal sales generation relative to the asset base.

In summary, the total asset turnover ratio indicates improving efficiency in asset utilization over the analyzed period. The consistent upward trend, particularly from late 2022, suggests effective management strategies and operational improvements in generating revenue from the company’s assets.


Equity Turnover

Medtronic PLC, equity turnover calculation (quarterly data)

Microsoft Excel
Jan 23, 2026 Oct 24, 2025 Jul 25, 2025 Apr 25, 2025 Jan 24, 2025 Oct 25, 2024 Jul 26, 2024 Apr 26, 2024 Jan 26, 2024 Oct 27, 2023 Jul 28, 2023 Apr 28, 2023 Jan 27, 2023 Oct 28, 2022 Jul 29, 2022 Apr 29, 2022 Jan 28, 2022 Oct 29, 2021 Jul 30, 2021 Apr 30, 2021 Jan 29, 2021 Oct 30, 2020 Jul 31, 2020
Selected Financial Data (US$ in millions)
Net sales
Shareholders’ equity
Long-term Activity Ratio
Equity turnover1
Benchmarks
Equity Turnover, Competitors2
Abbott Laboratories
Elevance Health Inc.
Intuitive Surgical Inc.
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).

1 Q3 2026 Calculation
Equity turnover = (Net salesQ3 2026 + Net salesQ2 2026 + Net salesQ1 2026 + Net salesQ4 2025) ÷ Shareholders’ equity
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The equity turnover ratio for the analyzed period demonstrates a generally increasing trend, with some fluctuations. Initially, the ratio remained stable at 0.56 for the first two quarters. A gradual increase is then observed, reaching 0.61 in the fifth and sixth quarters. This upward momentum continues, albeit with minor variations, until the fourteenth quarter, where the ratio reaches 0.64.

A more pronounced increase occurs in the subsequent periods. The ratio climbs to 0.68 in the sixteenth and seventeenth quarters, then further to 0.70 in the nineteenth and twentieth quarters. The final quarters show a slight increase, peaking at 0.72 in the twenty-fourth and twenty-fifth quarters.

Equity Turnover Trend
The equity turnover ratio generally increased from 0.56 to 0.72 over the analyzed period. This suggests that the company is becoming more efficient in generating sales from its shareholders’ equity. The increase indicates a potentially improved utilization of equity financing to drive revenue.
Short-Term Fluctuations
While the overall trend is upward, there are minor fluctuations in the ratio. For example, a slight decrease is observed between the eighth and ninth quarters, and again between the seventeenth and eighteenth. These fluctuations may be attributable to seasonal sales patterns or other short-term business factors.
Recent Performance
The most recent quarters (twenty-third through twenty-fifth) show a stabilization around the 0.71-0.72 range. This suggests that the rate of improvement in equity turnover may be slowing, although it remains at a relatively high level compared to the beginning of the analyzed period.

In summary, the equity turnover ratio indicates a positive trend in the company’s ability to generate sales relative to its equity base. The consistent increase suggests effective management of equity financing and improved operational efficiency. The recent stabilization warrants continued monitoring to assess whether further improvements can be achieved.